Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zj Huadi Pharma Group Pharma Development Co. Ltd. manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This specific action is located in 1 distinct art unit. A practitioner managing this portfolio interacts with 1 distinct examiner to address the outstanding issues.
The busiest examiner for this entity is LY, KRISTINA ELISABETH, who is currently responsible for 1 busiest examiner pending office action. This figure matches the total number of 1 pending office action for the entire portfolio. This means the prosecution workload is entirely handled by this examiner. Such a structure allows for a direct and consistent dialogue between the applicant and the USPTO.
Because the work is limited to 1 distinct art unit, the technical arguments required for these filings are specific to that unit's standards. The presence of 1 distinct examiner means that the legal strategy does not need to account for different examiner behaviors across the applications. The data shows a prosecution environment where all active matters are funneled through LY, KRISTINA ELISABETH, which simplifies the administrative oversight of the Zj Huadi Pharma Group Pharma Development Co. Ltd. company patent portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18483293 | METHOD FOR SEPARATING AND PURIFYING INFLUENZA VIRUS-LIKE PARTICLES (VLPS) USING AQUEOUS TWO-PHASE SYSTEM (ATPS) | LY, KRISTINA ELISABETH | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18483293 | METHOD FOR SEPARATING AND PURIFYING INFLUENZA VIRUS-LIKE PARTICLES (VLPS) USING AQUEOUS TWO-PHASE SYSTEM (ATPS) | LY, KRISTINA ELISABETH | 1663 | §103 | Non-Final OA | — | Pending | Oct 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZj Huadi Pharma Group Pharma Development Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kristina Elisabeth Ly has the most, with 1 of Zj Huadi Pharma Group Pharma Development Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
